Oren Livne counsels clients from startups to multinationals on variety of corporate and transactional matters globally, including license and collaboration agreements, commercial contracts, venture capital financings, mergers and acquisitions, and general corporate matters. His clients include life sciences, technology, and emerging growth companies. Oren is a guest lecturer at New York University entrepreneurship classes and has authored several intellectual property articles.
Oren brings first-hand, client-side licensing experience to his legal practice. Before becoming a lawyer, he co-founded a university technology transfer office and managed its licensing operations. He handled the licensing of an international patent portfolio in the light emitting diode and energy areas.
While at New York University School of Law, Oren was a Jacobson Leadership Program in Law and Business Scholar and an Intellectual Property Law Scholar. He also earned his M.B.A. from New York University’s Leonard N. Stern School of Business, where he was a Glucksman Fellow and Stern Scholar. He earned his B.S. in chemical engineering from Rutgers University, where he graduated at the top of his class.
Shire in its agreement with Mirum Pharmaceuticals pursuant to which Mirum has obtained exclusive global rights to develop and market maralixibat, an oral inhibitor of the apical sodium dependent bile acid transporter, and Shire has received undisclosed financial consideration and an equity position in Mirum
Amarin in its collaboration agreement with Mochida Pharmaceutical for the development and commercialization of drug products based on the omega-3 acid, EPA, to treat patients at risk of cardiovascular disease
Celgene in its collaboration agreement with Prothena to develop new therapies for a broad range of neurodegenerative diseases
Radius Health in its license and development agreement with Teijin relating to abaloparatide-SC in Japan
Takeda in its collaboration agreement with Cardurion Pharmaceuticals
Celgene in its global immuno-oncology collaboration with BeiGene to advance PD-1 inhibitor program for solid tumor cancers
SK Capital Partners in its acquisition of D.B. Western Inc.-Texas, an owner and operator of a formaldehyde and formaldehyde derivatives plant located in Texas
Shire in its worldwide development and commercialization collaboration with Parion Sciences relating to ENaC inhibitors for dry eye disease and other ophthalmic indications
Multiple clients in license, research, option, service, and other agreements with various universities including Rutgers University, Princeton University, John Hopkins University, Purdue University, University of Maryland, Hebrew University, and University of South Florida
Incyte in its global strategic collaboration with Merus for the research, discovery, development and commercialization of bispecific antibodies with a focus on immuno-oncology
Takeda in its collaboration with Ultragenyx to develop and commercialize therapies for rare genetic diseases
Incyte in the acquisition of Ariad’s European operations and in-license of Iclusig® in Europe
SK Capital Partners in its acquisition of the Textile Chemicals, Paper Specialties, and Emulsions businesses of Clariant, representing approximately $1.3 billion in revenues from 25 facilities worldwide
BioClinica in its sale to JLL Partners, Inc. for $123 million in a going-private transaction
Large pharmaceutical company, in its sale of manufacturing plants in Colorado, Germany and France
New York University, 2012, M.B.A., With Distinction
New York University School of Law, 2012, J.D.
Rutgers University, 1996, B.S. (Chemical Engineering), With Highest Honors
U.S. Patent and Trademark Office
Awards and Affiliations
Member, Tau Beta Pi (Engineering Honor Society)
Member, Beta Gamma Sigma (Business School Honor Society)
Member, Licensing Executives Society
Member, New York State Bar Association
Member, New Jersey State Bar Association
Member, American Intellectual Property Law Association